


Product data sheet



MedKoo Cat#: 330244 Name: Segetalin B CAS#: 164991-89-3 Chemical Formula: C ₂₄ H ₃₂ N ₆ O ₅ Exact Mass: 484.2434 Molecular Weight: 484.56	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:

Segetalin B is natural product isolated from Seeds of *Vaccaria Segetalis*. Segetalin B demonstrated to have an estrogen-like activity.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	250	515.94

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.06 mL	10.32 mL	20.64 mL
5 mM	0.41 mL	2.06 mL	4.13 mL
10 mM	0.21 mL	1.03 mL	2.06 mL
50 mM	0.04 mL	0.21 mL	0.41 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

To be determined

In vivo study

- Lan X, Ma H, Cheng Q, Xiao Y, Zou L, Yuan Z, Luo J. SIRT1/Notch1 signal axis involves in the promoting effect of Segetalin B on bone formation. *Drug Dev Res.* 2022 Dec;83(8):1845-1857. doi: 10.1002/ddr.22001. Epub 2022 Oct 7. PMID: 36207817.

7. Bioactivity

Biological target:

Segetalin B, a cyclopentapeptide from *Vaccaria segetalis*, possesses estrogen-like activity.

In vitro activity

To be determined

In vivo activity

SB is a potential therapeutic option for postmenopausal osteoporosis (PMOP). In ovariectomized (OVX) rats, SB treatment significantly decreased bone loss, inhibited calcium and phosphorus loss, elevated ALP activity, upregulated Runx2, Osterix, and SIRT1, and downregulated NICD and Hes1.

Product data sheet



Reference: Drug Dev Res. 2022 Dec;83(8):1845-1857. <https://pubmed.ncbi.nlm.nih.gov/36207817/>

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.